Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma

British Journal of Cancer

Volumn 114, Issue 5, 2016, Pages 510-518

  Middleton, Gary ^a,b   Greenhalf, William ^c,d   Costello, Eithne ^c,d   Shaw, Victoria ^c   Cox, Trevor ^d   Ghaneh, Paula ^c,d   Palmer, Daniel H ^c,d   Neoptolemos, John P ^c,d  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

apoptosis; chemotherapy; immunogenicity; inflammatory cytokines; pancreatic adenocarcinoma

Indexed keywords

C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CAPECITABINE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; TERTOMOTIDE; ANTINEOPLASTIC AGENT; CANCER VACCINE; DEOXYCYTIDINE; IL6 PROTEIN, HUMAN; PEPTIDE FRAGMENT; TELOMERASE;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOIMMUNOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; ELECTROCORTICOGRAPHY; FEMALE; HUMAN; IMMUNE RESPONSE; LIMIT OF DETECTION; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CARCINOMA, PANCREATIC DUCTAL; CELL PROLIFERATION; DELAYED HYPERSENSITIVITY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; C-REACTIVE PROTEIN; CA-19-9 ANTIGEN; CANCER VACCINES; CAPECITABINE; CARCINOMA, PANCREATIC DUCTAL; CELL PROLIFERATION; DEOXYCYTIDINE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; HYPERSENSITIVITY, DELAYED; INTERLEUKIN-6; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES; TELOMERASE;

EID: 84959296248     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.468     Document Type: Article

References (30)

1. Annels NE, Shaw VE, Gabitass RF, Billingham L, Corrie P, Eatock M, Valle J, Smith D, Wadsley J, Cunningham D, Pandha H, Neoptolemos JP, Middleton G. (2014). The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. Cancer Immunol Immunother. 63: 175-183.
2. Bauer C, Sterzik A, Bauernfeind F, Duewell P, Conrad C, Kiefl R, Endres S, Eigler A, Schnurr M, Dauer M. (2014). Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(-) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model. Cancer Immunol Immunother. 63: 321-333.
3. Brandt D, Volkmann X, Anstatt M, Langer F, Manns MP, Schulze-Osthoff K, Bantel H. (2010). Serum biomarkers of cell death for monitoring therapy response of gastrointestinal carcinomas. Eur J Cancer. 46: 1464-1473.
4. Corcoran RB, Contino G, Deshpande V, Tzatsos A, Conrad C, Benes CH, Levy DE, Settleman J, Engelman JA, Bardeesy N. (2011). STAT3 plays a critical role in KRAS-induced pancreatic cancer tumorigenesis. Cancer Res. 71: 5020-5029.
5. Cummings J, Ranson M, Lacasse E, Ganganagari JR, St-Jean M, Jayson G, Durkin J, Dive C. (2006). Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer. 95: 42-48.
6. Deng Z, Yang C, Deng H, Yang A, Geng T, Chen X, Ma A, Liu Z. (2006). Effects of GM-CSF on the stem cells mobilization and plasma C-reactive protein levels in patients with acute myocardial infarction. Int J Cardiol. 113: 92-96.
7. Dive C, Smith RA, Garner E, Ward T, George-Smith SS, Campbell F, Greenhalf W, Ghaneh P, Neoptolemos JP. (2010). Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. Br J Cancer. 102: 577-582.
8. Emens LA, Middleton G. (2015). The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 3: 436-443.
9. Galetto A, Buttiglieri S, Forno S, Moro F, Mussa A, Matera L. (2003). Drug- And cell-mediated antitumor cytotoxicities modulate crosspresentation of tumor antigens by myeloid dendritic cells. Anticancer Drugs. 14: 833-843.
10. Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade 3rd SM, Nemunaitis JJ, Stella PJ, Pipas JM, Wainberg ZA, Manges R, Garrett WM, Hunter DS, Clark J, Leopold L, Sandor V, Levy RS. (2015). Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol. 33: 4039-4047.
11. Kang TH, Mao CP, Lee SY, Chen A, Lee JH, Kim TW, Alvarez RD, Roden RB, Pardoll D, Hung CF, Wu TC. (2013). Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res. 73: 2493-2504.
12. Kanterman J, Sade-Feldman M, Biton M, Ish-Shalom E, Lasry A, Goldshtein A, Hubert A, Baniyash M. (2014). Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. Cancer Res. 74: 6022-6035.
13. Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz Jr. LA, Donehower RC, Jaffee EM, Laheru DA. (2013). Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 36: 382-389.
14. Lechner MG, Liebertz DJ, Epstein AL. (2010). Characterization of cytokine induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol. 185: 2273-2284.
15. Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, Solt S, Dorman A, Wamwea A, Yager A, Laheru D, Wolfgang CL, Wang J, Hruban RH, Anders RA, Jaffee EM, Zheng L. (2014). Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res. 2: 616-631.
16. Mace TA, Ameen Z, Collins A, Wojcik S, Mair M, Young GS, Fuchs JR, Eubank TD, Frankel WL, Bekaii-Saab T, Bloomston M, Lesinski GB. (2013). Pancreatic cancer-Associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res. 73: 3007-3018.
17. Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, Coxon F, Ross P, Madhusudan S, Roques T, Cunningham D, Falk S, Wadd N, Harrison M, Corrie P, Iveson T, Robinson A, McAdam K, Eatock M, Evans J, Archer C, Hickish T, Garcia-Alonso A, Nicolson M, Steward W, Anthoney A, Greenhalf W, Shaw V, Costello E, Naisbitt D, Rawcliffe C, Nanson G, Neoptolemos J. (2014). Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol. 15: 829-840.
18. Neoptolemos J, Greenhalf W, Cox T, Costello E, Shaw V, Valle J, Coxon F, Wadsley J, Propper D, Ross P, Madhusudan S, Roques T, Cunningham D, Eatock M, Iveson T, Patel K, Garcia-Alonso A, Nanson G, Middleton G. (2014). Predictive cytokine biomarkers for survival in patients with advanced pancreatic cancer randomized to sequential chemoimmunotherapy comprising gemcitabine and capecitabine (GemCap) followed by the telomerase vaccine GV1001 compared 'to concurrent chemoimmunotherapy in the TeloVac phase III trial. J Clin Oncol. 32: 5s 4121.
19. Nishikawa T, Hagihara K, Serada S, Isobe T, Matsumura A, Song J, Tanaka T, Kawase I, Naka T, Yoshizaki K. (2008). Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression. J Immunol. 180: 3492-3501.
20. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, Frelinger JA, Robinson BW. (2003). Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than crosstolerizing host tumor-specific CD8 T cells. J Immunol. 170: 4905-4913.
21. Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D. (2012). Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell. 21: 836-847.
22. Quelle FW, Sato N, Witthuhn BA, Inhorn RC, Eder M, Miyajima A, Griffin JD, Ihle JN. (1994). JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region. Mol Cell Biol. 14: 4335-4341.
23. Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, Wamwea A, Bigelow E, Lutz E, Liu L, Yao S, Anders RA, Laheru D, Wolfgang CL, Edil BH, Schulick RD, Jaffee EM, Zheng L. (2015). PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. J Immunother. 38: 1-11.
24. Stromnes IM, Brockenbrough JS, Izeradjene K, Carlson MA, Cuevas C, Simmons RM, Greenberg PD, Hingorani SR. (2014). Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut. 63: 1769-1781.
25. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. (2005). Gemcitabine selectively eliminates splenic Gr-1-/CD11b- myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 11: 6713-6721.
26. Szkandera J, Stotz M, Absenger G, Stojakovic T, Samonigg H, Kornprat P, Schaberl-Moser R, Alzoughbi W, Lackner C, Ress AL, Seggewies FS, Gerger A, Hoefler G, Pichler M. (2014). Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br J Cancer. 110: 183-188.
27. Takeuchi S, Baghdadi M, Tsuchikawa T, Wada H, Nakamura T, Abe H, Nakanishi S, Usui Y, Higuchi K, Takahashi M, Inoko K, Sato S, Takano H, Shichinohe T, Seino K, Hirano S. (2015). Chemotherapy-derived inflammatory responses accelerate the formation of immunosuppressive myeloid cells in the tissue microenvironment of human pancreatic cancer. Cancer Res. 75: 2629-2640.
28. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92: 205-216.
29. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366: 2443-2454.
30. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C, Ghiringhelli F. (2010). 5-Fluorouracil selectively kills tumor-Associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70: 3052-3061.